Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151086 · ClinicalTrials.gov registry record · Phase 1
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00151086 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 33 participants.
The verdict
NCT00151086, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of hormone refractory prostate cancer. The investigators will determine the tolerable dose of (oral) vinorelbine in combination with (oral) estramustine, and evaluate the efficacy of this treatment for patients with hormone-refractory prostate cancer.
Interventions
- DRUG Vinorelbine
- DRUG Estramustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2001-12 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151086
The ClinicalTrials.gov registry entry for NCT00151086 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vinorelbine is the first listed.
NCT00151086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151086 about?
NCT00151086 is a clinical study titled "Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer". Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of hormone refractory prostate cancer. The investigators will determine the tolerable dose of (oral) vinorelbine in c...
What is the current status of trial NCT00151086?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2001-12. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00151086?
The interventions under investigation include: Vinorelbine (DRUG), Estramustine (DRUG).
Who is sponsoring clinical trial NCT00151086?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.